Remarkably, FO treatment could counteract the decreased expression of zo-1 when applied to APP/PS1 mice, which provides evidence that ω3-PUFAs could be used as an early intervention agent for protecting BBB integrity in AD. The gene discussed is APP; the disease is Alzheimer disease.